Back to News
quantum-computing

Australian Consortium to Develop Quantum ‘Brain-on-Chip’ Platform for Alzheimer’s Discovery - Quantum Computing Report

Google News – Quantum Computing
Loading...
2 min read
0 likes
⚡ Quantum Brief
An Australian consortium led by the University of Melbourne secured $2.1M AUD to develop a quantum “brain-on-chip” platform for accelerating Alzheimer’s, epilepsy, and schizophrenia drug discovery. The platform merges 3D human neural micro-tissues with diamond-based quantum sensors, enabling real-time, high-resolution measurement of neural activity—outperforming traditional animal or 2D models. Diamond Voltage Imaging Microscopy (DVIM), developed by Chromos Labs, uses diamond micropillars to detect neuronal signals non-invasively, eliminating toxic labels or electrodes. Key partners include Quantum Brilliance (scalable diamond chips) and Axol Biosciences (human iPSC-derived neurons), aiming to reduce drug development risks by providing early human-relevant data. Success could cut reliance on costly human trials by enabling lab-based efficacy and toxicity testing, potentially transforming neurological research.
Australian Consortium to Develop Quantum ‘Brain-on-Chip’ Platform for Alzheimer’s Discovery - Quantum Computing Report

Summarize this article with:

Australian Consortium to Develop Quantum ‘Brain-on-Chip’ Platform for Alzheimer’s Discovery An Australian consortium led by the University of Melbourne has been awarded $2.1 million AUD ($1.47 million USD) by the Australian Government’s Critical Technologies Challenge Program (CTCP) to develop a quantum-enabled “brain-on-chip” platform. The project aims to accelerate the discovery and screening of treatments for neurological diseases, including Alzheimer’s, epilepsy, and schizophrenia. By integrating 3D human neural micro-tissues with quantum sensing, the platform provides a high-resolution, real-time method to measure functional neural activity, offering a more accurate preclinical model than traditional animal or 2D cellular studies. The technical core of the platform involves integrating Tessara Therapeutics’ RealBrain® 3D micro-tissues with a diamond-based quantum sensing approach developed by Chromos Labs. This method, known as Diamond Voltage Imaging Microscopy (DVIM), utilizes diamond micropillar arrays to optically detect millivolt-scale electrical signals from neurons without the need for invasive electrodes or potentially toxic fluorescent labels. In its current phase, the consortium is expanding the sensor’s field of view to capture comprehensive network-state data across entire micro-tissue cultures. The consortium includes Quantum Brilliance, which provides the manufacturing pathway for scalable diamond sensor chips, and Axol Biosciences, which supplies standardized human iPSC-derived neurons. This interdisciplinary effort seeks to de-risk neurological drug development—historically one of the most failure-prone areas in biopharma—by providing human-relevant data early in the pipeline. Successful validation of the prototype could significantly reduce the reliance on expensive human trials by allowing researchers to evaluate therapeutic efficacy and toxicity in a laboratory setting. For further details on the diamond voltage imaging technology and the consortium’s roadmap, consult the official announcement from the University of Melbourne here. March 3, 2026 Mohamed Abdel-Kareem2026-03-03T05:45:29-08:00 Leave A Comment Cancel replyComment Δ This site uses Akismet to reduce spam. Learn how your comment data is processed.

Read Original

Tags

quantum-computing

Source Information

Source: Google News – Quantum Computing